From Wikipedia, the free encyclopedia
Jump to: navigation, search

BufferGel is the brand name of a spermicide and microbicide gel which is being tested for its potential development into a preventative medicine to stop the transmission of HIV.


In macaques, after BufferGel's effect on microflora and pH were measured by vaginal colposcopy and rectal lavage researchers determined that it fit the safety profile of a drug which could be tested on humans.[1]

A phase I clinical trial done on women in India, Thailand gave supporting evidence that users tolerate the drug well.[2] A similar trial in the United States also showed drug tolerance.[3]


  1. ^ Zeitlin, L.; Hoen, T. E.; Achilles, S. L.; Hegarty, T. A.; Jerse, A. E.; Kreider, J. W.; Olmsted, S. S.; Whaley, K. J.; Cone, R. A.; Moench, T. R. (2001). "Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models". Sexually transmitted diseases 28 (7): 417–423. doi:10.1097/00007435-200107000-00010. PMID 11460027. 
  2. ^ Wijgert, Janneke van de; Andrew Fullem; Clifton Kelly; Sanjay Mehendale; Sungwal Rugpao; Newton Kumwenda; Zvavahera Chirenje; Smita Joshi; Nancy Padian; Robert Bollinger; Kenrad Nelson (2001). "Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites". Journal of Acquired Immune Deficiency Syndromes (Philadelphia: Lippincott Williams & Wilkins) 26 (1): 21–27. doi:10.1097/00042560-200101010-00003. 
  3. ^ Mayer, K. H.; Peipert, J.; Fleming, T.; Fullem, A.; Moench, T.; Cu-Uvin, S.; Bentley, M.; Chesney, M.; Rosenberg, Z. (2001). "Safety and Tolerability of BufferGel, a Novel Vaginal Microbicide, in Women in the United States". Clinical Infectious Diseases 32 (3): 476–482. doi:10.1086/318496. PMID 11170957. 

External links[edit]